Utilization of Decentralized Clinical Trial (DCT) elements expanded rapidly during the COVID‑19 pandemic, when traditional research pathways were disrupted and remote participation became essential. After the pandemic, Sanford built on the operational and regulatory momentum gained to broaden both the scope and reach of its DCT program. This work continues through strong collaboration with key internal partners and external stakeholders, ensuring the program evolves to meet patient needs, regulatory expectations, and community priorities.
CEU: 1.00 ACRP
Speaker:
Lora Black, RN, MPH, OCN, ACRP-CP, Vice President of Clinical Research, Sanford Health